Loracarbef

Loracarbef is an antibiotic, belongs to new class of beta-lactams, the carbacephins. Loracarbef is a synthetic structural analogue of cefaclor (a second-generation cephalosporin), but more stable against β-lactamases. it''s antimicrobial spectrum is similar to that of cefaclor. The clinical efficacy of Loracarbef is comparable to that of amoxicillin and amoxicillin/clavulanic acid in patients with upper or lower respiratory tract infections and is also comparable to cefaclor in treating patients with lower respiratory tract, skin, skin structure, and urinary tract infections. It was approved by FDA in December 1991.'

Brands
Adult Dose
Dose: 200 mg
Single Dose: 200 (200)
Frequency: 12 hourly
Route: PO
Instructions: For skin and soft tissue infections: Should be given for 7 days.
Neonatal
Paedriatic
Dose: 7.5 mg/kg
Single Dose: 7.5 (7.5)
Frequency: 12 hourly
Route: For uncomplicated infections.
Instructions:
Characteristics
. It is of Synthetic origin. . The Molecular Weight of Loracarbef is 367.80. Its pKa is 2.
Contraindications
Loracarbef is contraindicated in conditions like Hypersensitivity.
Effects
The severe or irreversible adverse effects of Loracarbef, which give rise to further complications include Pseudomembranous colitis, Thrombocytopenia, Maculopapular rash, Eosinophilia, Leukopenia.Loracarbef produces potentially life-threatening effects which include Acute intestinal nephritis. which are responsible for the discontinuation of Loracarbef therapy.The symptomatic adverse reactions produced by Loracarbef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Vomiting, Anorexia, Diarrhea, Abdominal pain, Rashes.
Indications
Loracarbef is primarily indicated in conditions like Acute bacterial pneumonia, Acute maxillary sinusitis, Acute pharyngitis, Acute tonsillitis, Hormone-mediated secretory diarrhea (can be benefit in refactory cases), Otitis media, Secondry bacterial infection of acute bronchitis, Sinusitis, Skin infections, Skin structure infections, UTI.
Interactions
No data regarding the interactions of Loracarbef was found.
Interfrence
+ve Coomb`s testsElevation of LDH
Risks
Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Cap, Susp Store at room temperature.
Warnings
Loracarbef should not be given to patients known to be hypersensitive to it or to other beta-lactams because of the possibility of cross-sensitivity. It should be used cautiously in patients with impaired renal function. A reduction in dose may be required. Renal and hematological status should be monitored during prolonged and high dose therapy.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.